п		

EUROPEAN PATENT APPLICATION

_			
ര മ	Application	number:	82104854,7

. 60 Int. CL: A 61 K 31/16

- Date of filing: 27.05.82
- © Date of publication of application: 07.12.83 Bulletin 83/49
- (7) Applicant: Bernstein, Joel E., M.D., 615 Brierhill Road, Deerfield Illinois 60015 (US)
- (7) Inventor: Bernstein, Joel E., M.D., 615 Brieffill Road, Deerfield Illinois 60015 (US)
- Designated Contracting States: AT BE CH DE FR GB IT LI LU NIL SE
- Representative: Baillie; lain Cameron et al, c/o Ladas & Parry laartorplatz 5, D-8000 München 2 (DE)

- Antipsortatic composition.
- ② A composition for treating psoriatic skin in which capsaich is present in a pharmaceutically acceptable carrier in therapeutically acceptable concentrations of between about 0.01 and about 1 percent by weight. Subsequent exposure of the treated psoriatic skin to ultraviolet light in small doses alds treatment.

EP 0 095 512 A1

The present invention relates to an antipsoriatic composition.

Psoriasis is a common chronic skin condition for which exist today a limited number of modestly effective agents, these being primarily topical corticosteroids and coal tar preparations. Various topical steroids effectively used to treat psoriasis of the skin includes fluocinolone acetonide, flurandrenolide, and triamcinolone acetonide are usually applied as creams or ointments.

These topical steroids are most effective if covered with a polyethylene film which preferably is sealed with tape. Thin polyethylene gloves are used for treating the hands and fingers. Treatment of psoriatic skin can also include daily removal of the scales by applying soap and water and scraping gently with a soft brush, followed by the application of a keratolytic ointment.

I have observed psoriasis seems to be much less common in Mexicans and Orientals than in American Caucasians and Blacks. Mexicans and Orientals eat substantially more spicy food containing red pepper than either Caucasians or Blacks. Capsaicin (the active principle in red pepper that makes the red pepper hot) has been found to be an effective treatment for psoriasis of the skin when applied topically in divided doses. Exposure of the treated psoriatic skin to small doses of ultraviolet light also assists treatment.

The present invention provides an antipsoriatic composition comprising a pharmaceutically acceptable

carrier of a lotion, cream or ointment and capsaicin present in an amount not less than about 0.01 percent by weight of the carrier.

In the practice of the present invention, capsaicin is distributed according to known techniques in
various pharmaceutically acceptable carriers such as
emulsions, solutions, suspensions including lotions,
creams and ointments. Some of these carriers contain
volatile diluents such as alcohol, glycol and the like
and also may contain wetting agents, emulsifying and suspending agents.

Capsaicin the active ingredient in the psoriasis preparation is a pungent principle in fruit of the various species of Capsicum or Solanaceae (pepper plants). Chemically, Capsaicin is known as trans-8-methyl-N-vanillyl-6-nonenamide or (E)-N-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide. Its structure is:

20 .

Capsaicin, commercially available from the Sigma Chemical Company, is preferably present in the pharmaceutically acceptable carrier in an amount of not less than 0.01 percent by weight and is preferably present in the range of from about 0.01 percent by weight to about 1 percent by weight.

If capsaicin is present in the pharmaceutically acceptable carrier in an amount less than about 0.01 percent by weight, then there is insufficient concentration of the capsaicin to provide effective therapy. If the capsaicin is present in an amount greater than about 1 percent by weight of the pharmaceutically acceptable carrier,

then the reaction of the psoriatic skin to the topical application is too painful. I have found the initial treatment of psoriatic skin with capsaicin results in an intense red painful reaction but the psoriatic skin be
5 comes quite tolerant to capsaicin applications upon subsequent treatment.

After treatment of patients with capsaicin in a pharmaceutically acceptable carrier, exposure to small amounts of ultraviolet light in the range of between about 3 to 5 MED per exposure in some cases hastens clearing and produces a better therapeutic benefit than the use of capsaicin alone. MED stands for "minimum erythemal dose", see the Handbook of Nonprescription Drugs, Sixth Edition, American Pharmaceutical Association, 1979. The capsaicin is preferably administered topically in divided doses 2 to 4 times a day with partial clearing of the psoriasis being observable in a five to ten day range.

The following examples further illustrate the present invention:

20

EXAMPLE 1

An ointment containing 0.01% by weight capsaicin was applied twice daily to the abdomen by a 28 year old white patient with extensive psoriasis involving most of the body. A plain emollient ointment was applied to the other areas of the skin. Within seven days of treatment the abdomen was nearly clear of psoriatic lesions, while the rest of the body was unchanged.

EXAMPLE 2

A .05% by weight capsaicin solution was applied 30 to psoriatic elbow lesions of a 30 year old white patient with mild psoriasis limited to the elbows. The solution was applied 2 to 3 times daily. The patient was first observed again two weeks later and the elbows were completely clear of psoriatic lesions.

35

EXAMPLE 3

A cream having .1% by weight capsaicin was applied 3 times a day by a 25 year old white patient with psoriasis affecting primarily the extensor surfaces of the arms and legs. Within 7 days of application redness

had decreased dramatically, scaling was reduced and the lesions had decreased significantly in size.

A 1% by weight solution of capsaicin was prepared in an aqueous/alcohol vehicle and applied 4 times 5 daily to the arms, legs, chest and back of a 58 year old black patient with psoriasis. Almost complete resolution of the psoriatic lesions was observed after 5 days of such treatment.

EXAMPLE 5

applied 4 times daily to the arms of a 49 year old white patient with psoriasis over the extensor surfaces of both arms. One arm was exposed to ultraviolet light for from 2 to 5 minutes in increasing doses every day for 8 days using a hot quartz lamp as the source of the ultraviolet light. After 8 days both arms were significantly improved. However, the arm exposed to ultraviolet light was completely clear of psoriatic lesions, while the other arm still had some small lesions.

20

25

EXAMPLE 6

A .5% by weight capsaicin ointment was applied twice daily by a 42 year old black patient with psoriasis involving the arms, legs, back, abdomen, and buttock.

After 1 week the patient showed significant clearing of the lesions and at this time exposure to small (2-3 minutes) of ultraviolet light was initiated daily with resulting total clearing noted by the end of the following week.

It will be apparent to those skilled in the art that only the preferred embodiments have been described

30 by way of exemplification and that there are various modifications and alterations possible.

CLAIMS

- 1. An antipsoriatic composition comprising a pharmaceutically acceptable carrier of a lotion, cream or ointment and capsaicin present in an amount not less than about 0.01 percent by weight of the carrier.
- 2. The composition of claim 1, wherein said capsaicin is present in the range of from about 0.01 to about 1 percent by weight of said carrier.



EP 82 10 4654

	DOCUMENTS CONSI	DERED TO BE RELEVANT		.•
Category		indication, where appropriate, and passages	Retovant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 7)
X	Wirkungen des scharf schmecke	pharmakologischen Capsaicins, des nden Wirkstoffes pages 718-727 *	1-2	A 61 K 31/18
x	abstract no.5331 Ohio (US)	1970, page 228, 7b, Columbus,	1-2	
	and epidermal	uman skin, liver lysosomes" & J. 1. 1970, 54(2),		TECHNICAL FIELDS SEARCHED (Int. Cl. 7)
X	23341/2335a, Col K.E. SCHULTE e of the cintme activity of cap cintments" & M	TS, vol.52, 0, 1958, columns umbus, Ohio (US) t al.: "Influence nt base on the saicin-containing itt. Deut. pharm6 * the whole	1-2	A 61 K 31/00 C 07 C 103/00
		The ter		
	The present search report has b	een drawn up for all claims		
	Place of search THE HAGUE	Date of completion of the search 14–10–1982	MOREA	Examiner
Y: p	CATEGORY OF CITED DOCL articularly relevant if taken alone articularly relevant if combined w ocument of the same category echnological background on-written disclosure intermediate document	E: earlier pat after the fi bith another D: document L: document	ent document ling date cited in the ap cited for othe	